Posts tagged end-stage renal disease
Fresenius extends Endexo accord with Interface Biologics

Fresenius Medical Care (FSE:FME; NYSE:FMS) has extended its exclusive licensing agreement with closely-held Interface Biologics for use of the Endexo technology in chronic dialysis systems to cover the acute dialysis market, including continuous renal replacement therapy.

Interface BiologicsInterface’s Endexo is a self-locating fluoro-oligomeric additive that results in a passive surface that reduces platelet adhesion and activation, protein adsorption and thrombus formation in medical devices, potentially reducing the use of drugs such as heparin.

Read More